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Figures S1 - S5 
 
 
Figure S1. Effect of Vc1.1 point mutation analogues (100 nM) on HVA calcium channels in rat 
DRG neurons. (A) Bar graph shows inhibition of HVA calcium channel current amplitude by 
alanine substituted analogues of Vc1.1. Loop regions are highlighted by the dotted lines and grey 
horizontal bars. The asterisk indicates mutants with significantly decreased potency relative to 
Vc1.1 (unpaired Student’s t-test. * P < 0.05, ** P < 0.01 and *** P < 0.001). Similar to mouse 
DRG data, only G1A, D11A, E14A and I15A, retain activity at GABAB R-mediated inhibition of 
HVA calcium channels in DRG neurons. Dotted line indicates the level of I/IBa inhibition by Vc1.1. 
The number of experiments, n, is in parentheses. Data points are mean ± SEM. (B) Concentration-
response relationship for inhibition of HVA calcium channel currents by Vc1.1 and the active 
alanine substituted analogues in rat DRG neurons. Pooled data indicate the IC50 for Vc1.1 (black 
dashed line, 2.5 nM, n = 8-25), D11A (blue, 6.8 nM, n = 3-6), E14A (green, 23.1 nM, n = 3-6), 







Figure S2. Representative time courses of HVA calcium channel inhibition by single point Vc1.1 
mutants (A) Representative time course of peak IBa inhibition in the presence of 100 nM alanine-
substituted analogues of Vc1.1: D11A, E14A and N9A. (B) Aspartic acid substituted analogues of 
Vc1.1: N9D, G1D and H12D. (C) Lysine substituted analogues of Vc1.1: D11K, I15K and Y10K. 
(A-C) the first and second rows show the substituted analogue of Vc1.1 that is equipotent to Vc1.1 
and the third row shows the Vc1.1 analogues that are less potent than Vc1.1 on GABABR-mediated 
inhibition of HVA calcium channel currents.  In all experiments, the GABABR agonist baclofen (50 
µM) has been applied at the end of experiment. Bar indicate the duration of α-conotoxin or baclofen 
application. Inward IBa were evoked by voltage steps from a HP of −80 mV to −5, 0 or +5 mV 
applied at 0.1 Hz, based on the peak IBa amplitude (insets). Superimposed representative IBa traces 
(insets) obtained in the absence (black, a) and presence of peptide (red, b), and 50 µM baclofen 




Figure S3. NMR Hα secondary shift comparison of Vc1.1[D11A, E14A] (circles) and 
cVc1.1[D11A, E14A] (squares) with cVc1.1 (triangles) and Vc1.1 (diamonds) from residues 1 to 
16. All peptides exhibit almost identical secondary shift values across the entire sequence. NMR 





Figure S4. Inhibition of rat(r) α9α10 nAChRs expressed in Xenopus oocytes by 
cVc1.1[D11A,E14A]. Concentration-response relationship for cVc1.1[D11A,E14A] inhibition of 
ACh-evoked current amplitude giving an IC50 of 17.9 ± 2.6 µM. Current amplitudes (mean ± SEM, 
n = 3-8) were normalized to the response elicited by 10 µM ACh (corresponding to the EC50 value 
at rα9α10 nAChRs). Inset. Superimposed representative of ACh (10 µM)-evoked currents 





Tables S1 – S2 
Table S1. NMR chemical shifts for cVc1.1[D11A, E14A] at 280K (pH 3.5, referenced to 4,4-
dimethyl-4-silapentane-1-sulfonic acid (DSS) at 0 ppm). 
Residue HN Hα Additional Hs 
15Na 13Cb 
Gly1 8.691 3.79, 
3.93 
 108.7 Cα 48.9 
Cys2 8.83 4.59 Hβ 2.73, 3.22 122.1 Cα 60.5; Cβ 
44.3 
Cys3 8.25 4.33 Hβ 2.82, 3.27 113.2 Cα 58.8; Cβ 
43.8 
Ser4 7.85 4.43 Hβs 3.97 114.8 Cα 63.0; Cβ 
66.4 
Asp5 7.92 5.20 Hβ 2.70, 3.18 124.1 Cα 52.4; Cβ 
43.8 
Pro6 - 4.26 Hβ 1.99, 2.37; Hγ 2.06, 2.11; 
Hδ 3.92, 4.08 
- Cα 68.5; Cβ 
35.0; Cγ 30.2; 
Cδ 53.6 
Arg7 7.98 4.15 Hβs 1.89; Hγ 1.64, 1.73; Hδs 




Cα 61.2; Cβ 
32.3; Cγ 29.9; 
Cδ 45.7; 
Cys8 8.09 4.41 Hβ 3.26, 4.23 121.4 Cα 62.0; Cβ 
43.8 
Asn9 9.02 4.35 Hβs 2.86 121.7 Cα 59.1; Cβ 
41.6 
Tyr10 7.90 4.16 Hβ 3.01, 3.19 117.5 Cα 62.6; Cβ 
40.9 
Ala11 7.40 4.10 Hβs 1.31 117.9 Cα 55.0; Cβ 
21.8 
His12 7.84 5.06 Hβ 3.05, 3.25 115.9 Cα 56.6; Cβ 
31.3 
Pro13 - 4.48 Hβ 1.96, 2.27; Hγ 1.95; Hδ 
3.38, 3.47 
- Cα 67.5; Cβ 
34.0; Cγ 30.0; 
Cδ 52.9 
Ala14 8.41 4.24 Hβs 1.44  120.6 Cα 64.6; Cβ 
21.2 
Ile15 7.47 4.24 Hβ 1.99; Hγ 1.20, 1.62, 0.87; 
Hδ 0.80 
114.1 Cα 56.8; Cβ 
41.5; Cγ 15.5, 
30.2; Cδ 15.6 
Cys16 8.021 4.99 Hβ 2.74. 3.30 118.4 Cα 56.9; Cβ 
40.9 
Gly17 8.36 3.86, 
4.07 
- 110.6 Cα 48.7 
Gly18 8.45 3.85, 
4.00 
- 110.0 Cα c 
Ala19 8.21 4.37 Hβs 1.40 124.1 Cα 54.8; Cβ 
 7
21.9 
Ala20 8.19 4.29 Hβs 1.39 122.8 Cα 55.1; Cβ 
21.9 
Gly21 8.14 3.86, 
4.01 
- 107.8 Cα 47.5 
Gly22 8.31 3.93, 
4.11 
- -c Cα 47.2 




Table S2. Structure statistics for cVc1.1[D11A, E14A] 
Experimental restraints  
Distance restraints  
Total NOE 78 
     Intraresidue 28 
     Sequential (|i − j| = 1) 37 
     Medium range (|i − j| < 4) 12 
     Long range (|i − j| > 5) 1 
Hydrogen-bond restraints 0 
Total Dihedral-angle restraints 39 
     φ 17 
     ψ 16 
     χ1 6 
Total number of restraints per residue 5.3 
Target function (Å) 0.36 ± 0.016 
Root-mean-square deviation to mean coordinate structure (Å)  
     Backbone atoms (residues 2 – 16) 0.21 ± 0.11 
     All heavy atoms (residues 2 – 16) 0.61 ± 0.13 
Stereochemical qualityb  
     Residues in most favoured Ramachandran region (%) 91.0 ± 5.3 
     Residues in allowed Ramachandran region (%) 9 
     Ramachandran outliers (%) 0 
     Unfavourable side chain rotamers (%) 21.6 ± 7.7 
     Cβ deviations >0.25 Å 0 
     Clash score, all atoms 0 
     Overall MolProbity score 1.943 ± 0.287 
 
aRoot-mean-square deviation values were calculated over the entire structure 
bStereochemical quality was assessed via MolProbity {Chen, 2010 #1826}. Clash score is the 
number of steric overlaps >0.4 Å per 103 atoms 
 
 
